Press release: Uppsala,
In 2022, Dicot started a research project with
According to the company, the project - in which a custom-designed method is used to produce cells and grow them - has been successful in demonstrating at a laboratory scale that the technology works. Therefore, the project will now progress to larger-scale testing. At the same time, a patent application is submitted to the Swedish Patent and Registration Office to protect this way of producing the starting material. The action will be followed by further patent applications on several other relevant markets.
"We continue to consistently advance our positions to broaden and strengthen the patent protection in accordance with our IP strategy. Our cell culture method is at the forefront and after a successful project with
For further information, please contact:
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
https://news.cision.com/dicot-ab--publ-/r/dicot-applies-for-patent-covering-new-manufacturing-technology,c3907174
https://mb.cision.com/Main/17172/3907174/2533307.pdf
(c) 2024 Cision. All rights reserved., source